Loading...

Intellectia LogoIntellectia
AI Trading Bot
Features
Markets
News
Resources
Pricing
Get Started
  1. Home
  2. Stock
  3. DARE
DARE logo

DARE Should I Buy

-
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
OverviewStock Price PredictionTechnicalValuationFinancialsEarningsShould I BuyNews & Events
an image of Intellectia Logoan image of Intellectia

Most Trusted AI Platform for Winning Trades

TwitterYoutubeQuoraDiscordLinkedinTelegram

Copyright © 2026 Intellectia.AI. All Rights Reserved.

Company

  • Home
  • Contact
  • About Us
  • Press
  • Privacy
  • Terms of Service
  • Service Terms of Use

Resources

  • Blog
  • Tutorial
  • Help Center
  • Affiliate Program

Markets

  • Market Analysis
  • Crypto
  • Featured Screeners
  • AI Earnings Calendar
  • Market Movers
  • Stock Monitor
  • Economic Calendar
  • All US Stocks
  • All Cryptos

Tools

  • Dividend Calculator
  • Dividend Yield Calculator
  • Options Profit Calculator

Features

  • QuantAI Alpha Pick
  • SwingMax Portfolio
  • Swing Trading
  • AI Stock Picker
  • Whales Auto Tracker
  • Daytrading Center
  • Patterns Detection
  • AI Screener
  • Financial AI Agent
  • Backtesting Playground
  • AI Earnings Prediction
  • Stock Monitor
  • Technical Analysis

News

  • Overview
  • Top News
  • Daily Market Brief
  • Earnings Analysis
  • Newswire
  • Stock News
  • Crypto News
  • Institution News
  • Congress News
  • Monitor News

Compare

  • TradingView
  • SeekingAlpha
Intellectia

Should You Buy Dare Bioscience Inc (DARE) Today? Analysis, Price Targets, and 2026 Outlook.

Conclusion
Hold
Latest Price
2.050
1 Day change
-1.44%
52 Week Range
9.190
Analysis Updated At
2026/07/03
Should I buy Analysis is updated weekly. For real time "Should I Buy" analysis, please sign up to get free answers.

DARE is not a strong buy right now for a beginner, long-term investor with $50,000-$100,000 to deploy. The technical setup is mildly constructive, but the lack of recent news, no clear analyst upgrade momentum, neutral insider/hedge fund activity, and no strong proprietary buy signal make this a wait-and-watch name rather than an immediate purchase. If the investor is impatient and wants to act now, I would not buy this stock today.

Technical Analysis

DARE is showing a modestly bullish but not decisive trend. MACD histogram is positive at 0.0174, though it is contracting, which suggests momentum is weakening. RSI_6 at 51.282 is neutral and does not indicate strong buying pressure. The moving averages are aligned bullishly with SMA_5 > SMA_20 > SMA_200, which supports the broader trend. Price is near the pivot at 2.092 and sitting between support at 2.004 and resistance at 2.18, so the stock is in a tight range without a breakout signal. Overall, the chart is positive but not strong enough to justify an aggressive long-term buy.

Positive Catalysts

  • Technically, the stock has a bullish moving average structure and a positive MACD histogram. The price is holding near pivot support, which may provide a short-term floor. There are no negative news events in the latest week, and the broader market environment is only slightly weak.

Neutral/Negative Catalysts

  • No news in the recent week means there is no event-driven catalyst to support a near-term move. Hedge funds and insiders are both neutral, which shows limited conviction from sophisticated buyers. The stock trend model points to only weak expected returns over the next day, week, and month. AI Stock Picker shows no signal today, and SwingMax also shows no recent signal.

Financial Performance

No usable latest-quarter financial snapshot was provided because the financial data returned an error. As a result, I cannot confirm revenue growth, margin trends, or quarter-over-quarter performance for the latest reported season. That weakens the case for a beginner long-term investor because there is no current financial evidence to support a strong thesis.

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

No analyst rating or price target change data was provided, so there is no clear trend in Wall Street estimates to support a buy decision. Based on the available information, Wall Street pros appear neutral at best: there is no visible upgrade momentum, no clear price target revisions, and no evidence of broad bullish consensus. The cons view is stronger right now because the lack of analyst support, no recent news, and no proprietary buy signal outweigh the mildly positive technical picture.

Wall Street analysts forecast DARE stock price to rise
2 Analyst Rating
Wall Street analysts forecast DARE stock price to rise
2 Buy
0 Hold
0 Sell
Moderate Buy
Current: 2.080
sliders
Low
8
Averages
10
High
12
Current: 2.080
sliders
Low
8
Averages
10
High
12
Maxim
Jason McCarthy
Hold
to
Buy
upgrade
$8
AI Analysis
2025-09-04
Reason
Maxim
Jason McCarthy
Price Target
$8
AI Analysis
2025-09-04
upgrade
Hold
to
Buy
Reason
Maxim analyst Jason McCarthy upgraded Dare Bioscience to Buy from Hold with an $8 price target.

People Also Watch